AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Episurf Board/Management Information 2017

Jul 26, 2017

3157_iss_2017-07-26_8f7b0d94-ec0b-4d8f-a90a-080f8cc1bef3.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Management group changes in Episurf Medical

Episurf Medical (NASDAQ: EPIS B) today announces that Dan Griffiths, Head of Marketing, will leave the company during the month ofAugust. "Dan has been instrumental in driving our marketing initiatives and we very much appreciate his contribution to Episurf" says Pål Ryfors, CEOof Episurf Medical. Dan Griffiths has been based in the UK since joining Episurf inApril 2016. Dan Griffiths says, "as the company re-structures the marketing department, reallocating it to Sweden, it is natural for me to seek new opportunities." Fredrik Zetterberg, Head of Sales Nordic and Benelux, will assume the position as Acting Head of Marketing.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: [email protected]

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.45 CET on 26 July 2017.